IBD Patients Face Varying Colorectal Cancer Risks Based on Dysplasia Grade

Got story updates? Submit your updates here. ›

A recent study by researchers at Karolinska Institutet and NYU Grossman School of Medicine has shed light on the long-term risk of developing precancerous lesions, known as dysplasia, and colorectal cancer among individuals living with inflammatory bowel disease (IBD). The findings emphasize that dysplasia is not a uniform entity, and the risk of progression to colorectal cancer varies significantly depending on the grade of dysplasia.

Why it matters

These findings underscore the critical need for individualized surveillance strategies for IBD patients, as traditional colonoscopy methods may not be sufficient. The research highlights the importance of tailoring the frequency and intensity of screening based on a patient's specific dysplasia grade to ensure timely detection and management of precancerous lesions.

The details

The study analyzed data from over 54,000 IBD patients, providing the most comprehensive estimates to date. Researchers found that among those without baseline dysplasia, only 2.3% developed advanced colorectal neoplasia (high-grade dysplasia or colorectal cancer) during follow-up. However, this risk jumped to 5.3% for those with indefinite dysplasia, and a concerning 8.3% for those with low-grade dysplasia. Most alarmingly, 40% of patients with high-grade dysplasia developed colorectal cancer, often within just one year.

• The study was published in February 2026.

What they’re saying

What’s next

Future research will likely focus on developing more precise risk stratification tools to identify patients at highest risk of dysplasia progression, exploring novel surveillance methods that are less invasive and more effective, optimizing treatment strategies to minimize both inflammation and infection risk, and personalized medicine approaches tailored to individual patient characteristics.